Abstract
Hepatocellular carcinoma (HCC) ranks the second most lethal tumor globally and is the fourth leading cause of cancer-related death worldwide. Unfortunately, HCC is commonly at intermediate tumor stage or advanced tumor stage, in which only some palliative treatment can be used to offer a limited overall survival. Due to the high heterogeneity of the genetic, molecular, and histological levels, HCC makes the prediction of preoperative transarterial chemoembolization (TACE) efficacy and the development of personalized regimens challenging. In this study, a new multi-modal point-of-care system is employed to predict the response of TACE in HCC by a concept of integrating multi-modal large-scale data of clinical index and computed tomography (CT) images. This multi-modal point-of-care predicting system opens new possibilities for predicting the response of TACE treatment and can help clinicians select the optimal patients with HCC who can benefit from the interventional therapy.
Highlights
Liver cancer is the second most lethal tumor after pancreatic cancer and ranks the fourth leading cause of cancer-related death worldwide (Craig et al, 2020; Villanueva et al, 2019; Tao et al, 2020)
In order to predict the response of transarterial chemoembolization (TACE) for Hepatocellular carcinoma (HCC) therapy, we developed a point-of-care system by a concept of integrating multi-modal large-scale data of computed tomography (CT) imaging and clinical indexes (Figure 1A)
This artificial intelligent predicting system could be divided into two parts: the computed tomography image-based predicting response of TACE and the clinical index-based evaluation of HCC therapy
Summary
Liver cancer is the second most lethal tumor after pancreatic cancer and ranks the fourth leading cause of cancer-related death worldwide (Craig et al, 2020; Villanueva et al, 2019; Tao et al, 2020). Hepatocellular carcinoma (HCC), which is the most common form of liver cancer (∼90% of liver cancer), remains a health challenge in the world (Llovet et al, 2021; Yu et al, 2020). In order to predict the prognosis of patients with HCC, the Barcelona Clinic Liver Cancer (BCLC) staging classification, which is approved by European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD), has emerged as the standard classification in recent years (Llovet et al, 2008; Vitale et al, 2011; Yang et al, 2012). Transarterial chemoembolization (TACE) is the recommended treatment for Barcelona stage B patients with localized liver disease and good liver function
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
